Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Successful treatment of a chronic-phase T-315I-mutated chronic myelogenous leukemia patient with a combination of imatinib and interferon-alfa

19 Jan 2012

Abstract excerpt

No abstract is available from the source.

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Chronic Lymphocytic Leukemia Research
Share to Chronic Myeloid Leukemia Treatments
Share to Eosinophilic Disorders and Syndromes

Source

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Identifiers

PMID: 22262141
DOI: 10.1007/s12185-012-1005-1

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 8 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Successful treatment of a chronic-phase T-315I-mutated chronic myelogenous leukemia patient with a combination of imatinib and interferon-alfaPMID 22262141Read ↗

Induction of sustained deep molecular response in a patient with chronic-phase T315I-mutated chronic myeloid leukemia with interferon-α monotherapy.Semantic proximity Read ↗

Case with chronic myeloid leukemia and T315I mutation, but still in complete molecular response under high dose imatinib therapy.Semantic proximity Read ↗

Dasatinib combined with interferon-alfa induces a complete cytogenetic response and major molecular response in a patient with chronic myelogenous leukemia harboring the T315I BCR-ABL1 mutation.Semantic proximity Read ↗

The effectiveness of interferon-α combined with imatinib in patient with chronic myeloid leukemia harboring T315I BCR-ABL1 mutation.Semantic proximity Read ↗

Novel targeted therapies to overcome imatinib mesylate resistance in chronic myeloid leukemia (CML)Semantic proximity Read ↗

Interferon-α Based Individualized Treatment of a High Risk Chronic Myelogenous Leukemia Patient Harboring T315I Mutation.Semantic proximity Read ↗

Chronic myelogenous leukemia: role of stem cell transplant in the imatinib era.Semantic proximity Read ↗

Tyrosine Kinase Inhibitor Treatment for Newly Diagnosed Chronic Myeloid Leukemia.Semantic proximity Read ↗

Therapeutic options against BCR-ABL1 T315I-positive chronic myelogenous leukemia.Semantic proximity Read ↗

Durable molecular response despite F317L and E255K mutations: Successful treatment of chronic myeloid leukemia with sequential imatinib, nilotinib and dasatinib.Semantic proximity Read ↗

Deep molecular response by IFN-α and dasatinib combination in a patient with T315I-mutated chronic myeloid leukemia.Semantic proximity Read ↗

Specific Targeted Therapy of Chronic Myelogenous Leukemia with ImatinibSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.